<DOC>
	<DOCNO>NCT00273936</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose , pharmacokinetics , anti-neoplastic response AVN-944 patient advance hematologic malignancy .</brief_summary>
	<brief_title>Trial AVN-944 Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>1 . Histologically cytologically confirm chronic myelogenous leukemia , acute myeloid leukemia , acute lymphocytic leukemia , multiple myeloma , Waldenstrom 's macroglobulinemia , nonHodgkin 's lymphoma Hodgkin 's disease . 2 . Patients must refractory , intolerant , decline receive establish therapy know provide clinical benefit condition . 3 . Age &gt; 18 year 4 . ECOG performance score 0 1 5 . Adequate renal function evidence serum creatinine &lt; 2.0 mg/dL 6 . Adequate hepatic function evidence : Serum total bilirubin &lt; 2.0 mg/dL ( Patients know Gilbert 's syndrome may total bilirubin value 3 mg/dL . ) Alkaline phosphatase &lt; 3X upper limit normal ( ULN ) reference lab ( &lt; 5X ULN consider related underlying disease ) SGOT/SGPT &lt; 3X ULN reference lab ( &lt; 5X ULN consider related underlying disease 7 . Patients must recover clinically significant effect prior surgery , radiotherapy antineoplastic therapy . 8 . Patients legal representative must able read , understand provide write informed consent participate trial . 9 . Women childbearing potential well fertile men partner must agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) . 1 . Patients uncontrolled active infection 2 . Prior treatment inosine5monophosphate dehydrogenase ( IMPDH ) inhibitor 3 . History prior malignancy within past 5 year except curatively treat nonmelanoma skin cancer , cervical intraepithelial neoplasia , localized prostate cancer current prostate specific antigen ( PSA ) &lt; 1.0 mg/dL Patients curatively treated malignancy evidence metastatic disease may enter discussion Medical Monitor . 4 . Patients know hypersensitivity component AVN944 5 . Patients receive concurrent investigational therapy receive investigational therapy within 14 day first schedule day dose ( investigational therapy define treatment currently regulatory authority approve indication ) . Clinically significant toxicity therapy must resolve &lt; Grade 2 . 6 . Grade 2 peripheral neuropathy 7 . Patients pregnant lactate 8 . Any intercurrent medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . 9 . History solid organ transplant 10 . Known HIV hepatitis B C ( active , previously treat )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>